Acumen Pharma's ACU193 Shows Potential in Alzheimer's Trial; Bullish View for EnerSys
- July 16th, 2023
- 421 views
Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) announced positive topline results from the Phase 1 INTERCEPT-AD trial evaluating the company's ACU193, a clinical-stage antibody therapy targeting amyloid beta oligomers (AβOs) in early Alzheimer's disease (AD).
The trial met primary and secondary objectives, demonstrating proof-of-mechanism for ACU193. Remarkably, higher dose cohorts showed rapid and significant amyloid plaque reduction, paving the way for potential monthly dosing.
On Friday, $ABOS closed at $6.28, reflecting an increase of $0.16 (+2.61%).
In other news, EnerSys (NYSE: ENS), a leading provider of stored energy solutions for industrial applications, received coverage initiation from CL King with a Buy rating and a price target of $137.
Considering $ENS closed at $110.68 on Friday, the suggested price target suggests a potential upside of $26.32 or approximately 23.77%, according to the investment firm's view.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login